Medical Equipments, Pharmaceuticals And Personal Care Products Tenders

Conclusion of a Non-Exclusive Discount Agreement According to § 130A Para. 8 Sgb V for the Active Ingredient Aclidinium Bromide, Atc R03bb05 for the Period May 1St, 2023 - April 30Th, 2025

Conclusion of a Non-Exclusive Discount Agreement According to § 130A Para. 8 Sgb V for the Active Substance Pimecrolimus, Atc D11ah02 for the Period May 1St, 2023 - April 30Th, 2025

Conclusion of a Non-Exclusive Discount Agreement According to § 130A Para. 8 Sgb V for the Active Substance Dydrogesterone Estradiol, Atc G03fa14 for the Period May 1St, 2023 - April 30Th, 2025

Conclusion of a Non-Exclusive Discount Agreement in Accordance with § 130A Paragraph 8 Sgb V for the Active Substance Dydrogesterone Estradiol (Excluding Sequential Preparations), Atc G03fb08 for the Period May 1St, 2023 - April 30Th, 2025

Purchase of Disposable Medical Instruments

Purchase of Disposable Medical Devices

Purchase of Medical Equipment

Conclusion of Non-Exclusive Discount Agreements in Accordance with §§ 130A Paragraph 8/130C Paragraph 1 Sgb V for Drugs with the Active Ingredient Tofacitinib (L04aa29) as Part of a So-Called Open House Model.

Conclusion of Non-Exclusive Discount Agreements According to §§ 130A Abs. 8/130C Abs. 1 Sgb V for Drugs with the Active Ingredient Aripiprazole, as a Depot Injection Suspension (N05ax12) - (Open House Model)

Conclusion of Non-Exclusive Discount Agreements According to §§ 130A Abs. 8/130C Abs. 1 Sgb V for Drugs with the Active Ingredient Formoterol and Aclidinium Bromide (R03al05) as Part of an Open House Model.